The UK MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that it was necessary to strengthen these warnings in the product information and on packaging to better inform healthcare professionals and patients of these known risks.

Contents:

• Advice for Healthcare Professionals
• Advice for Healthcare Professionals to Provide to Patients
• Background
• Review of the communication of the known risks of addiction, dependence, withdrawal and tolerance.
• Addiction, dependence, withdrawal and tolerance.
• Tapering Doses
• Resources for prescribers and dispensers
• Reporting advice
• Additional information
• Stakeholder engagement